TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 105 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q4 2015. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $596,000 | +3.1% | 147,819 | -2.0% | 0.00% | 0.0% |
| Q3 2016 | $578,000 | -11.1% | 150,906 | -0.1% | 0.00% | 0.0% |
| Q2 2016 | $650,000 | +13.8% | 151,120 | +22.5% | 0.00% | 0.0% |
| Q1 2016 | $571,000 | -52.9% | 123,353 | +2.0% | 0.00% | -50.0% |
| Q4 2015 | $1,213,000 | +35.4% | 120,917 | +0.7% | 0.00% | +100.0% |
| Q3 2015 | $896,000 | -87.5% | 120,115 | -20.3% | 0.00% | -88.9% |
| Q2 2015 | $7,150,000 | +84.9% | 150,725 | +42.8% | 0.01% | +80.0% |
| Q1 2015 | $3,868,000 | +30.4% | 105,568 | +41.4% | 0.01% | +25.0% |
| Q4 2014 | $2,966,000 | +132.4% | 74,681 | +16.7% | 0.00% | +100.0% |
| Q3 2014 | $1,276,000 | +49.4% | 63,984 | +1.1% | 0.00% | +100.0% |
| Q2 2014 | $854,000 | +100.9% | 63,302 | +62.3% | 0.00% | 0.0% |
| Q1 2014 | $425,000 | -17.2% | 38,997 | +2.8% | 0.00% | 0.0% |
| Q4 2013 | $513,000 | +39.4% | 37,919 | +17.2% | 0.00% | 0.0% |
| Q3 2013 | $368,000 | +84.0% | 32,367 | +13.9% | 0.00% | – |
| Q2 2013 | $200,000 | – | 28,428 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,048,642 | $3,219,000 | 0.50% |
| Virtus ETF Advisers LLC | 130,920 | $402,000 | 0.35% |
| 683 Capital Management, LLC | 600,000 | $1,842,000 | 0.16% |
| Tekla Capital Management LLC | 859,322 | $2,638,000 | 0.10% |
| DOW CHEMICAL CO /DE/ | 65,000 | $200,000 | 0.07% |
| Alambic Investment Management, L.P. | 115,834 | $356,000 | 0.05% |
| A.R.T. Advisors, LLC | 262,896 | $807,000 | 0.03% |
| Candriam S.C.A. | 520,613 | $1,598,000 | 0.03% |
| Man Group plc | 1,674,341 | $5,140,000 | 0.02% |
| Baker Brothers Advisors | 935,000 | $2,870,000 | 0.02% |